Top Markets
Coin of the day
Enochian Biosciences, Inc. Enochian Biosciences, Inc.

Enochian Biosciences, Inc.

ENOB
株式のランク #19951
Enochian Biosciences, Inc. is a pre-clinical biotechnology firm dedicated to... Enochian Biosciences, Inc. is a pre-clinical biotechnology firm dedicated to the research and advancement of novel pharmaceutical and biological agents. Its primary focus lies in developing treatments for a range of human diseases, including human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza, coronavirus infections, and various cancers. The company's leading investigational products encompass ENOB-HV-01, an autologous therapy aimed at achieving an HIV cure; ENOB-HV-11, a preventative HIV vaccine candidate; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, which targets the HBV polymerase. Beyond these primary programs, Enochian Biosciences' developmental pipeline also features ENOB-DC-11, an off-the-shelf dendritic cell vaccine designed for multiple solid tumors, and ENOB-DC-21, a non-specific vaccine intended for direct intratumoral injection. The company collaborates strategically with prominent research organizations such as The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Founded in 2017, Enochian Biosciences, Inc. operates from its headquarters in Los Angeles, California.
株価
$2.60
最終同期: 2023-08-29
時価総額
$145.54M
変化(1日)
9.24%
変化(1年)
0.00%
US
取引 Enochian Biosciences, Inc. (ENOB)

カテゴリー

Enochian Biosciences, Inc.(ENOB)の配当利回りの履歴
Enochian Biosciences, Inc.(銘柄コード: ENOB)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Enochian Biosciences, Inc.(ENOB)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)